New portable device aims to improve heart disease prevention

Canada’s cardiac system is organized around discrete events—symptom, appointment, test, diagnosis, and intervention—while heart disease progresses over months and years, often before a patient feels ill.

Gaps in the Current Model

Heart disease remains the nation’s second-leading cause of death and a primary driver of hospital admissions, yet the health network still emphasizes treatment after symptoms appear.

Prevention cannot be a mere slogan attached to a reactive framework; it requires tools that let clinicians detect meaningful change earlier rather than responding only when disease is evident.

Most cardiac care today relies on single-point assessments such as blood-pressure readings, electrocardiograms, imaging studies, or specialist consultations.

These snapshots accurately describe the patient’s condition at the moment of measurement, but they do not reliably reveal whether cardiac performance is improving or deteriorating between visits.

The approach is not intended for universal use nor as a replacement for established diagnostics; it targets clearly defined patient groups where the clinical question expands to “what is changing?” as well as “what is happening?”

A recent OurCare National Survey showed that 17 per cent of Canadians still lack a regular family doctor, nurse practitioner, or primary-care setting. Among those with a primary-care connection, only 37 per cent obtained an urgent appointment the same or next day, and just 28 per cent expressed satisfaction with the system.

When timely access to clinics, specialists, and hospital tests remains the exception, a prevention model that depends on repeated visits cannot succeed.

Simply flooding clinicians with more data does not create intelligence. The key is whether repeated, standardized measurements can be translated into clinically useful context, identifying stable patients, flagging those who need closer review, and escalating others to advanced testing.

Emerging Monitoring Technologies

Seismocardiography, which records subtle chest-wall vibrations generated by the heart’s mechanical activity, is designed to fill this monitoring gap.

One implementation is Recordis, a portable, non-invasive, clinical-grade platform developed by LLA Technologies. The device captures standardized mechanical cardiac data for review by qualified professionals, but it does not replace echocardiography or function as a standalone diagnostic.

Recordis exemplifies a broader effort to create a longitudinal cardiac intelligence layer that sits between episodic clinical encounters, offering baseline establishment, trend comparison, and support for clinicians assessing change between imaging episodes.

Canadian innovators are expanding such technologies to bring appropriate care closer to patients, generate more consistent information across appointments, and enable health systems to allocate scarce specialist resources more deliberately.

This challenge extends beyond national borders; any country confronting chronic disease, aging populations, and uneven access must manage conditions that evolve continuously within systems built around isolated encounters.

Innovation alone will not suffice if health systems lack pathways for evaluation, adoption, and funding. Provinces, health authorities, and research institutions are urged to develop structured pilots for longitudinal cardiac technologies, defining patient cohorts, clinical objectives, and escalation routes in advance.

These pilots should assess reliability, usability, equity, privacy, interoperability, and, most importantly, whether the information influences care decisions.

Moving Toward Integrated Care

Canada does not need to choose between trusted diagnostic tests and technologies that can extend their reach; the two must be connected.

Waiting for symptoms before mobilizing the most expensive parts of the system does not constitute prevention. Heart disease evolves continuously, and the care model must finally begin to do the same.

David Loban, CEO and President of LLA Technologies, emphasizes that Recordis™ aims to help people understand their heart health earlier and more effectively; the views expressed are his own, and Canada Healthwatch does not necessarily endorse them.